$LRCX

TALWALKAR ABHIJIT Y sold $6.1M of LRCX

TALWALKAR ABHIJIT Y sold 18,282 shares of LAM RESEARCH CORP (LRCX) at $335.00 ($6.12M total) on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TALWALKAR ABHIJIT Y
Published Jul 14, 2026, 4:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 4:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LRCX
Neutral
high confidence
Mentioned
$LRCX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRCXNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 18,282 shares at $335/share, totaling about $6.12M, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone does not introduce new operational or financial guidance.

03

What to watch

The filing does not state reasons for sale or any new company-specific information; any price reaction would likely be short-lived and sentiment-driven.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-14, transaction dated 2026-07-13.

Background

The article is an SEC Form 4 insider transaction disclosure for LAM Research Corp (LRCX).

Company-level read

Ticker impact

$LRCXNeutralHigh confidence
Context

Form 4 shows LRCX director Talwalkar sold 18,282 shares in an open-market transaction at $335/share on 2026-07-13 under a 10b5-1 plan.

Expected impact

Limited, likely sentiment-only impact; no clear directional fundamental catalyst from the filing alone.

Evidence & confidence

The filing is a routine Form 4 sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying earnings, guidance, or operational change disclosed.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may discount it.

Key entities

  • LRCX

    Lam Research Corp, issuer of the Form 4 insider sale.

  • TALWALKAR ABHIJIT Y

    Director who sold 18,282 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRCXMed

The Memory Crunch Is Bigger Than Expected. 1 Top Stock to Buy on the Dip (Hint: Not Micron or Sandisk)

Lam Research (LRCX) is benefiting from a memory chip supply crunch, with revenue up 26% and earnings up 39% in fiscal 2026. The company expects 52% revenue growth and 71% earnings growth in the current quarter. Deloitte projects memory manufacturer capex to rise significantly, favoring Lam's semiconductor equipment sales. Analysts forecast 62% EPS growth for fiscal 2027, with potential for further upside.

$LRCXMedAI 8/10

Ministry approves Lam Research's NT$9.8 billion Taiwan investment

Taiwan's Ministry of Economic Affairs approved Lam Research's NT$9.835 billion (US$310 million) investment in its Taiwan subsidiary for semiconductor equipment R&D. Other approved investments include Zhen Ding Technology's NT$3 billion in Boardtek Electronics, Nuvoton's 15 billion yen in its Japan unit, and Foxconn's US$57.01 million in Mitsubishi Fuso Bus.